lonafarnib has been researched along with deoxycytidine in 5 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (deoxycytidine) | Trials (deoxycytidine) | Recent Studies (post-2010) (deoxycytidine) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 18,160 | 4,652 | 8,898 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adjei, AA; Dy, GK | 1 |
| Caponigro, F; Chollet, P; de Balincourt, C; Fiedler, W; Fumoleau, P; Geoffrois, L; Lacombe, D; Peters, GJ; Ravaud, A; Theodore, C; Vermorken, JB | 1 |
| Basche, M; Chow, LQ; Eckhardt, SG; Gore, L; Grolnic, S; Morrow, M; O'Bryant, CL; Schultz, MK | 1 |
| Adema, AD; Honeywell, RJ; Peters, GJ; van der Born, K | 1 |
| Adjei, AA; Cutler, DL; Hurwitz, HI; Kaufmann, SH; Meadows, KL; Meyers, ML; Morse, MA; Petros, WP; Rosen, LS; Statkevich, P; Wong, NS; Zhu, Y | 1 |
1 review(s) available for lonafarnib and deoxycytidine
| Article | Year |
|---|---|
Farnesyltransferase inhibitors in breast cancer therapy.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; Fluorouracil; Humans; Mice; Neoplasm Proteins; Paclitaxel; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
3 trial(s) available for lonafarnib and deoxycytidine
| Article | Year |
|---|---|
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.
Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Farnesyltranstransferase; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Piperidines; Pyridines; Salvage Therapy; Survival Analysis; Urologic Neoplasms | 2005 |
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Farnesyltranstransferase; Fatigue; Female; Gemcitabine; HSP40 Heat-Shock Proteins; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Piperidines; Pyridines; Treatment Outcome; Vomiting | 2008 |
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Piperidines; Pyridines | 2011 |
1 other study(ies) available for lonafarnib and deoxycytidine
| Article | Year |
|---|---|
Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Dacarbazine; Deoxycytidine; Deoxyguanosine; DNA Adducts; DNA Methylation; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Mice; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Piperidines; Pyridines; Temozolomide | 2009 |